Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
Background: The aim of the study was to assess the effects of combination of bortezomib moderate dose and conti-nuous oral low dose melphalan and thalidomide and dexamethasone (BMTD regimen) in elderly patients aged ≥ 65 years with relapsed multiple myeloma (MM). Methods: Twenty four patients with...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
Series: | Journal of Research in Medical Sciences |
Subjects: | |
Online Access: | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2012;volume=17;issue=1;spage=8;epage=14;aulast=Azarm |
id |
doaj-f7f5e53d52064701936abf320523abd8 |
---|---|
record_format |
Article |
spelling |
doaj-f7f5e53d52064701936abf320523abd82020-11-25T01:45:42ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362012-01-01171814Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myelomaTaleb AzarmMojtaba AkbariArezo AzarmHamid MohagerBackground: The aim of the study was to assess the effects of combination of bortezomib moderate dose and conti-nuous oral low dose melphalan and thalidomide and dexamethasone (BMTD regimen) in elderly patients aged ≥ 65 years with relapsed multiple myeloma (MM). Methods: Twenty four patients with advanced MM were enrolled to receive eight 3-week treatment cycles with borte-zomib 1.3 mg/m2 on days 1, 4, 8, and 11 followed by three 5-week cycles with bortezomib 1.3 mg/m2 on days 1, 8, 15, and 22. Within all cycles, dexamethasone 24 mg/d was given intravenously on the day of bortezomib injection and the day thereafter. In addition, patients received oral treatment of melphalan at a dose of 5 mg/d continuously for twenty days for every cycle. Results: Mean age of study patients was 72.8 6.4 years. All patients that completed at least one treatment cycle were evaluated for response. Complete, partial, and minor responses occurred in 19%, 65% and 6% of patients, respectively. Overall response rate was 90% (efficacy analysis). Conclusions: This study demonstrated potent in vivo activity of combination therapy with BMTD regimen in patients with relapsed MM, with an acceptable safety profile and high overall response rate.http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2012;volume=17;issue=1;spage=8;epage=14;aulast=AzarmMultiple MyelomaBortezomibDexamethasoneMelphalanThalidomide |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Taleb Azarm Mojtaba Akbari Arezo Azarm Hamid Mohager |
spellingShingle |
Taleb Azarm Mojtaba Akbari Arezo Azarm Hamid Mohager Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma Journal of Research in Medical Sciences Multiple Myeloma Bortezomib Dexamethasone Melphalan Thalidomide |
author_facet |
Taleb Azarm Mojtaba Akbari Arezo Azarm Hamid Mohager |
author_sort |
Taleb Azarm |
title |
Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma |
title_short |
Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma |
title_full |
Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma |
title_fullStr |
Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma |
title_full_unstemmed |
Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma |
title_sort |
bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma |
publisher |
Wolters Kluwer Medknow Publications |
series |
Journal of Research in Medical Sciences |
issn |
1735-1995 1735-7136 |
publishDate |
2012-01-01 |
description |
Background: The aim of the study was to assess the effects of combination of bortezomib moderate dose and conti-nuous oral low dose melphalan and thalidomide and dexamethasone (BMTD regimen) in elderly patients aged ≥ 65 years with relapsed multiple myeloma (MM).
Methods: Twenty four patients with advanced MM were enrolled to receive eight 3-week treatment cycles with borte-zomib 1.3 mg/m2 on days 1, 4, 8, and 11 followed by three 5-week cycles with bortezomib 1.3 mg/m2 on days 1, 8, 15, and 22. Within all cycles, dexamethasone 24 mg/d was given intravenously on the day of bortezomib injection and the day thereafter. In addition, patients received oral treatment of melphalan at a dose of 5 mg/d continuously for twenty days for every cycle.
Results: Mean age of study patients was 72.8 6.4 years. All patients that completed at least one treatment cycle were evaluated for response. Complete, partial, and minor responses occurred in 19%, 65% and 6% of patients, respectively. Overall response rate was 90% (efficacy analysis).
Conclusions: This study demonstrated potent in vivo activity of combination therapy with BMTD regimen in patients with relapsed MM, with an acceptable safety profile and high overall response rate. |
topic |
Multiple Myeloma Bortezomib Dexamethasone Melphalan Thalidomide |
url |
http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2012;volume=17;issue=1;spage=8;epage=14;aulast=Azarm |
work_keys_str_mv |
AT talebazarm bortezomibincombinationwithlowdoseoralmelphalandexamethasoneandthalidomideforrelapsedelderlypatientswithmultiplemyeloma AT mojtabaakbari bortezomibincombinationwithlowdoseoralmelphalandexamethasoneandthalidomideforrelapsedelderlypatientswithmultiplemyeloma AT arezoazarm bortezomibincombinationwithlowdoseoralmelphalandexamethasoneandthalidomideforrelapsedelderlypatientswithmultiplemyeloma AT hamidmohager bortezomibincombinationwithlowdoseoralmelphalandexamethasoneandthalidomideforrelapsedelderlypatientswithmultiplemyeloma |
_version_ |
1725023324901212160 |